Life-saving technology

With the aim of making this life-saving technology available to all Canadians, Project ACTT is also:

  • Generating health economics data to accelerate government health coverage of ctDNA testing
  • Enhancing Imagia Canexia Health’s ctDNA test to cover more solid tumor cancer types
  • Localizing testing access by training laboratory staff to conduct testing in-house

For thousands of cancer patients each year, this minimally-invasive blood draw can be performed instead of surgical tissue biopsy to enable oncologists to select treatment options.

The test is currently available at no cost for lung cancer patients in Canada, and those with breast or lung cancers in Quebec. For patients with other types of cancer that may benefit from a liquid biopsy, a patient pay option is now available through OncoHelix. To learn more, visit https://oncohelix.org/ngs-testing/.

Testing Information

If you are a patient, you can learn more about how to access the test through your provider here.

If you are an oncologist/provider, you can learn more about test access for your patients here.

Tumour Types Tested

Lung cancer patients in Canada and breast cancer patients in Quebec.

Eligibility

Patients with suspected or known relapsed disease where ctDNA testing can detect resistance mutations. Patients with metastatic disease where ctDNA testing can detect resistance mutations. Patients with tumor not easily amenable to biopsy. Very ill patients with metastatic disease.

Turnaround Time

10 working days

Specimen Type

Blood

Cost

No cost for lung cancer patients in Canada, and those with breast or lung cancers in Quebec. For patients with other types of cancer that may benefit from a liquid biopsy, a patient pay option is now available through OncoHelix. To learn more, visit https://oncohelix.org/ngs-testing/.

A Global Blueprint

Using Project ACTT as a blueprint, Imagia Canexia Health is now building an ecosystem of partners to replicate the model globally and offset burdens on health systems by ensuring all eligible cancer patients have access to life-saving testing.

Imagia Canexia Health’s ctDNA test, Follow It®, offered through a growing network of global partners, is commercially available and detects close to 90% of clinically actionable mutations in all cancer types. Further, Imagia Canexia Health offers a unique partnership model for local laboratories to set up biomarker testing in-house quickly and effectively. Imagia Canexia Health provides its technology and methodology for labs to run testing in-house, while also providing a complete bioinformatics reporting pipeline.

Download Project ACTT Global Brochure

Partner with us

Partnering with Imagia Canexia Health is a cost-effective way to provide quality precision oncology testing and supports efforts to establish and secure reimbursement in localities. This will enable hospitals and laboratories to run ctDNA testing in-house, leading to a sustainable solution regardless of COVID-19 and other health system impacts.

We are seeking to further build our consortium of global pharmaceutical, laboratory, academic, and oncology partners for:

  • Sample collection
  • Bringing ctDNA testing in-house
  • Program funding support
  • Health economic studies
  • In-country health system expertise

Contact Us

Stay Connected

Don’t miss out on news, webinars, and other resources from Imagia Canexia Health. Subscribe to our mailing list to stay up to date on the latest. You can opt-out at any time.

Resources